non-alcoholic steatohepatitis (NASH)
Viscient Biosciences is Leveraging 3D Bioprinting for Drug Discovery
Biotechnology companies are uncovering new methods to develop drugs across a range of therapeutic areas. Looking to demonstrate a commitment to drug discovery and moving away from traditional laboratory animal…
Keith Murphy: “We Believe We are Discovering the Next Step in Drug Development”
It’s been three years since Keith Murphy and Jeffrey Miner joined forces to create the biotechnology company Viscient Biosciences. In 2017, the co-founders had recently left their previous successful enterprises…
